Developments Adaptive partners with NeoGenomics to advance blood cancer monitoring Adaptive Biotechnologies (NASDAQ:ADPT) and NeoGenomics (NASDAQ:NEO) have announced a multi-year exclusive collaboration aimed at advancing minimal residual disease (MRD) monitoring options for patients with select blood... January 14, 2025